Shield Therapeutics said Tuesday that Australia’s Therapeutics Goods Administration has registered its lead product Feraccru in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.
Feraccru is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia, Shield noted.
The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for medicinal products (“therapeutic goods”).